Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 534

1.

Wnt Signaling Drives Prostate Cancer Bone Metastatic Tropism and Invasion.

Wang Y, Singhal U, Qiao Y, Kasputis T, Chung JS, Zhao H, Chammaa F, Belardo JA, Roth TM, Zhang H, Zaslavsky AB, Palapattu GS, Pienta KJ, Chinnaiyan AM, Taichman RS, Cackowski FC, Morgan TM.

Transl Oncol. 2020 Mar 24;13(4):100747. doi: 10.1016/j.tranon.2020.100747. [Epub ahead of print]

PMID:
32217460
2.

Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.

Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, Rowe SP, Ross AE, Gorin MA, Deville C, Greco SC, Wang H, Denmeade SR, Paller CJ, Dipasquale S, DeWeese TL, Song DY, Wang H, Carducci MA, Pienta KJ, Pomper MG, Dicker AP, Eisenberger MA, Alizadeh AA, Diehn M, Tran PT.

JAMA Oncol. 2020 Mar 26. doi: 10.1001/jamaoncol.2020.0147. [Epub ahead of print]

PMID:
32215577
3.

Extracellular vesicle isolation from human renal cancer tissue.

Zieren RC, Dong L, Pierorazio PM, Pienta KJ, de Reijke TM, Amend SR.

Med Oncol. 2020 Mar 14;37(4):28. doi: 10.1007/s12032-020-1346-1.

PMID:
32172294
4.

Perspectives in Oncology: a new article type for Medical Oncology.

Pienta KJ.

Med Oncol. 2020 Mar 7;37(3):21. doi: 10.1007/s12032-020-01349-x. No abstract available.

PMID:
32146528
5.

Cancer Cells and M2 Macrophages: Cooperative Invasive Ecosystem Engineers.

Myers KV, Pienta KJ, Amend SR.

Cancer Control. 2020 Jan-Dec;27(1):1073274820911058. doi: 10.1177/1073274820911058.

6.

The combination of size-based separation and selection-free technology provides higher circulating tumor cells detection sensitivity than either method alone in patients with metastatic prostate cancer.

Dong L, Zhang Z, Smith K, Kuczler M, Reyes D, Amend SR, Cho YK, Xue W, Pienta KJ.

BJU Int. 2020 Mar 1. doi: 10.1111/bju.15041. [Epub ahead of print]

PMID:
32115854
7.

CUE-101, a Novel E7-pHLA-IL2-Fc Fusion Protein, Enhances Tumor Antigen-Specific T-Cell Activation for the Treatment of HPV16-Driven Malignancies.

Quayle SN, Girgis N, Thapa DR, Merazga Z, Kemp MM, Histed A, Zhao F, Moreta M, Ruthardt P, Hulot S, Nelson A, Kraemer LD, Beal DR, Witt L, Ryabin J, Soriano J, Haydock M, Spaulding E, Ross JF, Kiener PA, Almo S, Chaparro R, Seidel R, Suri A, Cemerski S, Pienta KJ, Simcox ME.

Clin Cancer Res. 2020 Jan 21. doi: 10.1158/1078-0432.CCR-19-3354. [Epub ahead of print]

8.

NF-κB p50-deficient immature myeloid cell (p50-IMC) adoptive transfer slows the growth of murine prostate and pancreatic ductal carcinoma.

Suresh R, Barakat DJ, Barberi T, Zheng L, Jaffee E, Pienta KJ, Friedman AD.

J Immunother Cancer. 2020 Jan;8(1). pii: e000244. doi: 10.1136/jitc-2019-000244.

9.

Vas deferens infiltration by prostate cancer on prostate-specific membrane antigen-targeted 18F-DCFPyL positron emission tomography/computed tomography: A unique visual pattern.

Yin Y, Paller CJ, Pomper MG, Pienta KJ, Gorin MA, Rowe SP.

World J Nucl Med. 2019 Dec 18;18(4):424-427. doi: 10.4103/wjnm.WJNM_50_18. eCollection 2019 Oct-Dec.

10.

Uptake of prostate-specific membrane antigen-targeted 18F-DCFPyL in avascular necrosis of the femoral head.

Torga G, Yin Y, Pomper MG, Pienta KJ, Gorin MA, Rowe SP.

World J Nucl Med. 2019 Dec 18;18(4):416-419. doi: 10.4103/wjnm.WJNM_106_18. eCollection 2019 Oct-Dec.

11.

Letter to the Editor re: "Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake".

Werner RA, Pienta KJ, Pomper MG, Gorin MA, Rowe SP, Lodge MA, Bundschuh RA.

Mol Imaging Biol. 2020 Feb;22(1):19-21. doi: 10.1007/s11307-019-01452-0. No abstract available.

PMID:
31832870
12.

Prostate cancer research: The next generation; report from the 2019 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Sharp A, Ellis L, Jones J, Kaochar S, Larman HB, Quigley DA, Ye H, Simons JW, Pienta KJ, Soule HR.

Prostate. 2020 Feb;80(2):113-132. doi: 10.1002/pros.23934. Epub 2019 Dec 11. Review.

PMID:
31825540
13.

Generation of Heterogeneous Drug Gradients Across Cancer Populations on a Microfluidic Evolution Accelerator for Real-Time Observation.

Lin KC, Torga G, Sun Y, Pienta KJ, Sturm JC, Austin RH.

J Vis Exp. 2019 Sep 19;(151). doi: 10.3791/60185.

PMID:
31609331
14.

Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.

Chalfin HJ, Glavaris SA, Gorin MA, Kates MR, Fong MH, Dong L, Matoso A, Bivalacqua TJ, Johnson MH, Pienta KJ, Hahn NM, McConkey DJ.

Eur Urol Oncol. 2019 Sep 25. pii: S2588-9311(19)30130-0. doi: 10.1016/j.euo.2019.08.004. [Epub ahead of print]

PMID:
31563523
15.

Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis.

Dai J, Escara-Wilke J, Keller JM, Jung Y, Taichman RS, Pienta KJ, Keller ET.

J Exp Med. 2019 Dec 2;216(12):2883-2899. doi: 10.1084/jem.20190158. Epub 2019 Sep 23.

PMID:
31548301
16.

Gleason pattern 5 is associated with an increased risk for metastasis following androgen deprivation therapy and radiation: An analysis of RTOG 9202 and 9902.

Hamstra DA, Pugh SL, Lepor H, Rosenthal SA, Pienta KJ, Gomella L, Peters C, D'Souza DP, Zeitzer KL, Jones CU, Hall WA, Horwitz E, Pisansky TM, Souhami L, Hartford AC, Dominello M, Feng F, Sandler HM.

Radiother Oncol. 2019 Dec;141:137-143. doi: 10.1016/j.radonc.2019.08.020. Epub 2019 Sep 17.

PMID:
31540746
17.

Re: Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy of Clinically Localized, High Risk Prostate Cancer.

Dong L, Pienta KJ.

Eur Urol. 2020 Feb;77(2):285. doi: 10.1016/j.eururo.2019.08.028. Epub 2019 Aug 31. No abstract available.

PMID:
31477346
18.

Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.

Rowe SP, Li X, Trock BJ, Werner RA, Frey S, DiGianvittorio M, Bleiler JK, Reyes DK, Abdallah R, Pienta KJ, Gorin MA, Pomper MG.

J Nucl Med. 2020 Feb;61(2):183-188. doi: 10.2967/jnumed.119.227793. Epub 2019 Aug 26.

PMID:
31451492
19.

Detection and isolation of disseminated tumor cells in bone marrow of patients with clinically localized prostate cancer.

Cackowski FC, Wang Y, Decker JT, Sifuentes C, Weindorf S, Jung Y, Wang Y, Decker AM, Yumoto K, Szerlip N, Buttitta L, Pienta KJ, Morgan TM, Taichman RS.

Prostate. 2019 Oct;79(14):1715-1727. doi: 10.1002/pros.23896. Epub 2019 Aug 26.

PMID:
31449673
20.

Radiation Therapy in the Definitive Management of Oligometastatic Prostate Cancer: The Johns Hopkins Experience.

Deek MP, Yu C, Phillips R, Song DY, Deville C, Greco S, DeWeese TL, Antonarakis ES, Markowski M, Paller C, Denmeade S, Carducci M, Walsh PC, Pienta KJ, Eisenberger M, Tran PT.

Int J Radiat Oncol Biol Phys. 2019 Dec 1;105(5):948-956. doi: 10.1016/j.ijrobp.2019.08.008. Epub 2019 Aug 13.

21.

Can the interplay between androgen signaling and PSMA expression be leveraged for theranostic applications?

Batra JS, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Transl Androl Urol. 2019 Jul;8(Suppl 3):S263-S264. doi: 10.21037/tau.2019.03.13. No abstract available.

22.

Polyploid giant cancer cells: Unrecognized actuators of tumorigenesis, metastasis, and resistance.

Amend SR, Torga G, Lin KC, Kostecka LG, de Marzo A, Austin RH, Pienta KJ.

Prostate. 2019 Sep;79(13):1489-1497. doi: 10.1002/pros.23877. Epub 2019 Aug 2. Review.

PMID:
31376205
23.

Mannose Receptor-positive Macrophage Infiltration Correlates with Prostate Cancer Onset and Metastatic Castration-resistant Disease.

Zarif JC, Baena-Del Valle JA, Hicks JL, Heaphy CM, Vidal I, Luo J, Lotan TL, Hooper JE, Isaacs WB, Pienta KJ, De Marzo AM.

Eur Urol Oncol. 2019 Jul;2(4):429-436. doi: 10.1016/j.euo.2018.09.014. Epub 2018 Oct 19.

24.

Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer: An Update on Important Pitfalls.

Sheikhbahaei S, Werner RA, Solnes LB, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Semin Nucl Med. 2019 Jul;49(4):255-270. doi: 10.1053/j.semnuclmed.2019.02.006. Epub 2019 Mar 4. Review.

PMID:
31227049
25.

Prospective Evaluation of PSMA-Targeted 18F-DCFPyL PET/CT in Men with Biochemical Failure After Radical Prostatectomy for Prostate Cancer.

Rowe SP, Campbell SP, Mana-Ay M, Szabo Z, Allaf ME, Pienta KJ, Pomper MG, Ross AE, Gorin MA.

J Nucl Med. 2020 Jan;61(1):58-61. doi: 10.2967/jnumed.119.226514. Epub 2019 Jun 14.

PMID:
31201249
26.

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Impact of Tumor Burden on Normal Organ Uptake.

Werner RA, Bundschuh RA, Bundschuh L, Lapa C, Yin Y, Javadi MS, Buck AK, Higuchi T, Pienta KJ, Pomper MG, Lodge MA, Gorin MA, Rowe SP.

Mol Imaging Biol. 2020 Feb;22(1):190-197. doi: 10.1007/s11307-019-01375-w.

PMID:
31140110
27.

Semiquantitative Parameters in PSMA-Targeted PET Imaging with [18F]DCFPyL: Intrapatient and Interpatient Variability of Normal Organ Uptake.

Sahakyan K, Li X, Lodge MA, Werner RA, Bundschuh RA, Bundschuh L, Kulkarni HR, Schuchardt C, Baum RP, Pienta KJ, Pomper MG, Ross AE, Gorin MA, Rowe SP.

Mol Imaging Biol. 2020 Feb;22(1):181-189. doi: 10.1007/s11307-019-01376-9.

PMID:
31115751
28.

Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment.

Myers KV, Amend SR, Pienta KJ.

Mol Cancer. 2019 May 14;18(1):94. doi: 10.1186/s12943-019-1022-2. Review.

29.

Evaluation of Intense Androgen Deprivation Before Prostatectomy: A Randomized Phase II Trial of Enzalutamide and Leuprolide With or Without Abiraterone.

McKay RR, Ye H, Xie W, Lis R, Calagua C, Zhang Z, Trinh QD, Chang SL, Harshman LC, Ross AE, Pienta KJ, Lin DW, Ellis WJ, Montgomery B, Chang P, Wagner AA, Bubley GJ, Kibel AS, Taplin ME.

J Clin Oncol. 2019 Apr 10;37(11):923-931. doi: 10.1200/JCO.18.01777. Epub 2019 Feb 27.

30.

The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells.

Lin KC, Torga G, Sun Y, Axelrod R, Pienta KJ, Sturm JC, Austin RH.

Clin Exp Metastasis. 2019 Apr;36(2):97-108. doi: 10.1007/s10585-019-09958-1. Epub 2019 Feb 27.

PMID:
30810874
31.

Imaging and Characterization of Macrophage Distribution in Mouse Models of Human Prostate Cancer.

Copeland BT, Shallal H, Shen C, Pienta KJ, Foss CA, Pomper MG.

Mol Imaging Biol. 2019 Dec;21(6):1054-1063. doi: 10.1007/s11307-019-01318-5.

PMID:
30805886
32.

Novel Structured Reporting Systems for Theranostic Radiotracers.

Werner RA, Bundschuh RA, Bundschuh L, Fanti S, Javadi MS, Higuchi T, Weich A, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Herrmann K, Lapa C, Rowe SP.

J Nucl Med. 2019 May;60(5):577-584. doi: 10.2967/jnumed.118.223537. Epub 2019 Feb 22.

33.

Hereditary Spherocytosis Presenting as Diffuse Bone Marrow Activation and Splenomegaly on PSMA-Targeted 18F-DCFPyL PET/CT.

Gomez E, Tran PT, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Clin Nucl Med. 2019 Apr;44(4):e313-e314. doi: 10.1097/RLU.0000000000002489.

PMID:
30789396
34.

Metastatic prostate cancer remains incurable, why?

Dong L, Zieren RC, Xue W, de Reijke TM, Pienta KJ.

Asian J Urol. 2019 Jan;6(1):26-41. doi: 10.1016/j.ajur.2018.11.005. Epub 2018 Nov 29. Review.

35.

Recent advances in extracellular vesicle research for urological cancers: From technology to application.

Dong L, Zieren RC, Wang Y, de Reijke TM, Xue W, Pienta KJ.

Biochim Biophys Acta Rev Cancer. 2019 Apr;1871(2):342-360. doi: 10.1016/j.bbcan.2019.01.008. Epub 2019 Feb 7. Review.

PMID:
30738098
36.

Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment.

Li X, Jolly MK, George JT, Pienta KJ, Levine H.

Front Oncol. 2019 Jan 23;9:10. doi: 10.3389/fonc.2019.00010. eCollection 2019.

37.

PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework.

Reyes DK, Demehri S, Werner RA, Pomper MG, Gorin MA, Rowe SP, Pienta KJ.

Urol Case Rep. 2019 Jan 9;23:72-74. doi: 10.1016/j.eucr.2019.01.007. eCollection 2019 Mar.

38.

Prostate-specific markers to identify rare prostate cancer cells in liquid biopsies.

van der Toom EE, Axelrod HD, de la Rosette JJ, de Reijke TM, Pienta KJ, Valkenburg KC.

Nat Rev Urol. 2019 Jan;16(1):7-22. doi: 10.1038/s41585-018-0119-5. Review.

39.

Cooperation among cancer cells: applying game theory to cancer.

Archetti M, Pienta KJ.

Nat Rev Cancer. 2019 Feb;19(2):110-117. doi: 10.1038/s41568-018-0083-7. Review.

PMID:
30470829
40.

Optimization of prostate cancer cell detection using multiplex tyramide signal amplification.

Roy S, Axelrod HD, Valkenburg KC, Amend S, Pienta KJ.

J Cell Biochem. 2019 Apr;120(4):4804-4812. doi: 10.1002/jcb.28016. Epub 2018 Nov 2.

41.

Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.

Miyahira AK, Den RB, Carlo MI, de Leeuw R, Hope TA, Karzai F, McKay RR, Salami SS, Simons JW, Pienta KJ, Soule HR.

Prostate. 2019 Feb;79(3):244-258. doi: 10.1002/pros.23729. Epub 2018 Oct 31. Review.

PMID:
30381857
42.

Publisher Correction: 3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification.

Kalinin AA, Allyn-Feuer A, Ade A, Fon GV, Meixner W, Dilworth D, Husain SS, de Wet JR, Higgins GA, Zheng G, Creekmore A, Wiley JW, Verdone JE, Veltri RW, Pienta KJ, Coffey DS, Athey BD, Dinov ID.

Sci Rep. 2018 Oct 26;8(1):16142. doi: 10.1038/s41598-018-33574-w.

43.

AXL Is a Putative Tumor Suppressor and Dormancy Regulator in Prostate Cancer.

Axelrod HD, Valkenburg KC, Amend SR, Hicks JL, Parsana P, Torga G, DeMarzo AM, Pienta KJ.

Mol Cancer Res. 2019 Feb;17(2):356-369. doi: 10.1158/1541-7786.MCR-18-0718. Epub 2018 Oct 5.

44.

Uptake of Prostate-Specific Membrane Antigen-Targeted 18F-DCFPyL in Cerebral Radionecrosis: Implications for Diagnostic Imaging of High-Grade Gliomas.

Salas Fragomeni RA, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

Clin Nucl Med. 2018 Nov;43(11):e419-e421. doi: 10.1097/RLU.0000000000002280.

PMID:
30247210
45.

3D Shape Modeling for Cell Nuclear Morphological Analysis and Classification.

Kalinin AA, Allyn-Feuer A, Ade A, Fon GV, Meixner W, Dilworth D, Husain SS, de Wet JR, Higgins GA, Zheng G, Creekmore A, Wiley JW, Verdone JE, Veltri RW, Pienta KJ, Coffey DS, Athey BD, Dinov ID.

Sci Rep. 2018 Sep 12;8(1):13658. doi: 10.1038/s41598-018-31924-2. Erratum in: Sci Rep. 2018 Oct 26;8(1):16142.

46.

Stereotactic ablative radiation therapy for oligometastatic prostate cancer delays time-to-next systemic treatment.

Moyer CL, Phillips R, Deek MP, Radwan N, Ross AE, Antonarakis ES, Reyes D, Wright J, Terezakis SA, Song DY, DeVille C, Walsh PC, DeWeese TL, Carducci M, Schaeffer EM, Pienta KJ, Eisenberger M, Tran PT.

World J Urol. 2019 Dec;37(12):2623-2629. doi: 10.1007/s00345-018-2477-2. Epub 2018 Sep 6.

PMID:
30191396
47.

Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging.

Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Leal JP, Higuchi T, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP.

J Nucl Med. 2018 Dec;59(12):1857-1864. doi: 10.2967/jnumed.118.217588. Epub 2018 Sep 6.

48.

Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Yin Y, Werner RA, Higuchi T, Lapa C, Pienta KJ, Pomper MG, Gorin MA, Rowe SP.

J Nucl Med. 2019 Apr;60(4):511-516. doi: 10.2967/jnumed.118.217653. Epub 2018 Sep 6.

49.

O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis.

Taparra K, Wang H, Malek R, Lafargue A, Barbhuiya MA, Wang X, Simons BW, Ballew M, Nugent K, Groves J, Williams RD, Shiraishi T, Verdone J, Yildirir G, Henry R, Zhang B, Wong J, Wang KK, Nelkin BD, Pienta KJ, Felsher D, Zachara NE, Tran PT.

J Clin Invest. 2018 Nov 1;128(11):4924-4937. doi: 10.1172/JCI94844. Epub 2018 Sep 24.

50.

Molecular imaging reporting and data systems (MI-RADS): a generalizable framework for targeted radiotracers with theranostic implications.

Werner RA, Bundschuh RA, Bundschuh L, Javadi MS, Higuchi T, Weich A, Sheikhbahaei S, Pienta KJ, Buck AK, Pomper MG, Gorin MA, Lapa C, Rowe SP.

Ann Nucl Med. 2018 Oct;32(8):512-522. doi: 10.1007/s12149-018-1291-7. Epub 2018 Aug 14. Review.

Supplemental Content

Loading ...
Support Center